Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa
A candidate DNA vaccine pTHgagC expressing the immunodeficiency virus-1 (HIV-1) gag gene from South African isolate Du422 was constructed and characterised. The isolate was selected on the basis of being the closest to the South African subtype C consensus sequence. Sequence analysis of cytotoxic T...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2003-10, Vol.21 (27), p.4380-4389 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4389 |
|---|---|
| container_issue | 27 |
| container_start_page | 4380 |
| container_title | Vaccine |
| container_volume | 21 |
| creator | van Harmelen, Joanne H. Shephard, Enid Thomas, Robin Hanke, Tomáš Williamson, Anna-Lise Williamson, Carolyn |
| description | A candidate DNA vaccine pTHgagC expressing the immunodeficiency virus-1 (HIV-1)
gag gene from South African isolate Du422 was constructed and characterised. The isolate was selected on the basis of being the closest to the South African subtype C consensus sequence. Sequence analysis of cytotoxic T lymphocyte (CTL) epitopes showed that HIV subtype C-infected individuals have CTL responses to a number of epitopes present in the vaccine, but also revealed a more limited presence of subtype A- and any B-derived epitopes. A high level of expression of the immunogen was demonstrated in human cells and a potent, long-lived CTL response to a single inoculation of the DNA vaccine was elicited in BALB/c mice, which could be significantly increased by a boost vaccination at 4 weeks. This is the first candidate HIV-1 DNA vaccine employing the South African subtype C sequences, and constitutes a part of a vaccine scheduled to enter a clinical evaluation in South Africa in 2004. |
| doi_str_mv | 10.1016/S0264-410X(03)00406-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_18872695</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X03004067</els_id><sourcerecordid>3386726971</sourcerecordid><originalsourceid>FETCH-LOGICAL-c516t-98ad923ee266f6f684e632fd334d8f2f5e85ae889a94afbe7a57580bf6c0efc93</originalsourceid><addsrcrecordid>eNqN0UtrVDEYBuAgih2rP0EJiFIXR3O_rGQYW1souqiKGwmZnC80ZeZkTM4p9N-buWDBhUoWgeT5XhJehJ5T8pYSqt5dEaZEJyj5fkL4G0IEUZ1-gGbUaN4xSc1DNPtNjtCTWm8IIZJT-xgdUSGJtIzO0I9FHupYpjCmPGA_9Dhc--LDCCVVvzvMEXsc2lXq_Qj4_OJbR3GdluPdBvACf_g0x7c-hDQAjrngqzyN13geSwr-KXoU_arCs8N-jL6enX5ZnHeXnz9eLOaXXZBUjZ01vreMAzClYltGgOIs9pyL3kQWJRjpwRjrrfBxCdpLLQ1ZRhUIxGD5MXq9z92U_HOCOrp1qgFWKz9AnqqjxmimrGzw5O9QKkKZloT_ByVES60ZbfTlH_QmT2VoP25KWC6EsaIpuVeh5FoLRLcpae3LnaPEbTt1u07dtjBHuNt16nSbe3FIn5Zr6O-nDiU28OoAfA1-FYsfQqr3TjKrhd4Gvd87aFXcJiiuhgRDgD4VCKPrc_rHU34B45e7ng</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1549344894</pqid></control><display><type>article</type><title>Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>van Harmelen, Joanne H. ; Shephard, Enid ; Thomas, Robin ; Hanke, Tomáš ; Williamson, Anna-Lise ; Williamson, Carolyn</creator><creatorcontrib>van Harmelen, Joanne H. ; Shephard, Enid ; Thomas, Robin ; Hanke, Tomáš ; Williamson, Anna-Lise ; Williamson, Carolyn</creatorcontrib><description>A candidate DNA vaccine pTHgagC expressing the immunodeficiency virus-1 (HIV-1)
gag gene from South African isolate Du422 was constructed and characterised. The isolate was selected on the basis of being the closest to the South African subtype C consensus sequence. Sequence analysis of cytotoxic T lymphocyte (CTL) epitopes showed that HIV subtype C-infected individuals have CTL responses to a number of epitopes present in the vaccine, but also revealed a more limited presence of subtype A- and any B-derived epitopes. A high level of expression of the immunogen was demonstrated in human cells and a potent, long-lived CTL response to a single inoculation of the DNA vaccine was elicited in BALB/c mice, which could be significantly increased by a boost vaccination at 4 weeks. This is the first candidate HIV-1 DNA vaccine employing the South African subtype C sequences, and constitutes a part of a vaccine scheduled to enter a clinical evaluation in South Africa in 2004.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(03)00406-7</identifier><identifier>PMID: 14505921</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>AIDS Vaccines - immunology ; Amino Acid Sequence ; Animals ; Biological and medical sciences ; Chromium Radioisotopes ; Clinical trials ; Construction ; Cytotoxicity Tests, Immunologic ; Deoxyribonucleic acid ; DNA ; DNA vaccination ; DNA, Complementary - immunology ; Fundamental and applied biological sciences. Psychology ; Gag ; Genes ; Genes, gag - genetics ; Genomes ; HeLa Cells ; HIV ; HIV-1 - immunology ; HIV-1 subtype C ; Human immunodeficiency virus ; Human immunodeficiency virus 1 ; Humans ; Immunization ; Interferon-gamma - metabolism ; Lymphocytes ; Mice ; Mice, Inbred BALB C ; Microbiology ; Molecular Sequence Data ; Peptides ; Proteins ; South Africa ; T-Lymphocytes, Regulatory - immunology ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Vaccines, DNA - immunology ; Virology ; Viruses</subject><ispartof>Vaccine, 2003-10, Vol.21 (27), p.4380-4389</ispartof><rights>2003 Elsevier Science Ltd</rights><rights>2004 INIST-CNRS</rights><rights>Copyright Elsevier Limited Oct 1, 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c516t-98ad923ee266f6f684e632fd334d8f2f5e85ae889a94afbe7a57580bf6c0efc93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1549344894?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974,64362,64364,64366,72216</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15297477$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14505921$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Harmelen, Joanne H.</creatorcontrib><creatorcontrib>Shephard, Enid</creatorcontrib><creatorcontrib>Thomas, Robin</creatorcontrib><creatorcontrib>Hanke, Tomáš</creatorcontrib><creatorcontrib>Williamson, Anna-Lise</creatorcontrib><creatorcontrib>Williamson, Carolyn</creatorcontrib><title>Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>A candidate DNA vaccine pTHgagC expressing the immunodeficiency virus-1 (HIV-1)
gag gene from South African isolate Du422 was constructed and characterised. The isolate was selected on the basis of being the closest to the South African subtype C consensus sequence. Sequence analysis of cytotoxic T lymphocyte (CTL) epitopes showed that HIV subtype C-infected individuals have CTL responses to a number of epitopes present in the vaccine, but also revealed a more limited presence of subtype A- and any B-derived epitopes. A high level of expression of the immunogen was demonstrated in human cells and a potent, long-lived CTL response to a single inoculation of the DNA vaccine was elicited in BALB/c mice, which could be significantly increased by a boost vaccination at 4 weeks. This is the first candidate HIV-1 DNA vaccine employing the South African subtype C sequences, and constitutes a part of a vaccine scheduled to enter a clinical evaluation in South Africa in 2004.</description><subject>AIDS Vaccines - immunology</subject><subject>Amino Acid Sequence</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Chromium Radioisotopes</subject><subject>Clinical trials</subject><subject>Construction</subject><subject>Cytotoxicity Tests, Immunologic</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA vaccination</subject><subject>DNA, Complementary - immunology</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gag</subject><subject>Genes</subject><subject>Genes, gag - genetics</subject><subject>Genomes</subject><subject>HeLa Cells</subject><subject>HIV</subject><subject>HIV-1 - immunology</subject><subject>HIV-1 subtype C</subject><subject>Human immunodeficiency virus</subject><subject>Human immunodeficiency virus 1</subject><subject>Humans</subject><subject>Immunization</subject><subject>Interferon-gamma - metabolism</subject><subject>Lymphocytes</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Microbiology</subject><subject>Molecular Sequence Data</subject><subject>Peptides</subject><subject>Proteins</subject><subject>South Africa</subject><subject>T-Lymphocytes, Regulatory - immunology</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Vaccines, DNA - immunology</subject><subject>Virology</subject><subject>Viruses</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqN0UtrVDEYBuAgih2rP0EJiFIXR3O_rGQYW1souqiKGwmZnC80ZeZkTM4p9N-buWDBhUoWgeT5XhJehJ5T8pYSqt5dEaZEJyj5fkL4G0IEUZ1-gGbUaN4xSc1DNPtNjtCTWm8IIZJT-xgdUSGJtIzO0I9FHupYpjCmPGA_9Dhc--LDCCVVvzvMEXsc2lXq_Qj4_OJbR3GdluPdBvACf_g0x7c-hDQAjrngqzyN13geSwr-KXoU_arCs8N-jL6enX5ZnHeXnz9eLOaXXZBUjZ01vreMAzClYltGgOIs9pyL3kQWJRjpwRjrrfBxCdpLLQ1ZRhUIxGD5MXq9z92U_HOCOrp1qgFWKz9AnqqjxmimrGzw5O9QKkKZloT_ByVES60ZbfTlH_QmT2VoP25KWC6EsaIpuVeh5FoLRLcpae3LnaPEbTt1u07dtjBHuNt16nSbe3FIn5Zr6O-nDiU28OoAfA1-FYsfQqr3TjKrhd4Gvd87aFXcJiiuhgRDgD4VCKPrc_rHU34B45e7ng</recordid><startdate>20031001</startdate><enddate>20031001</enddate><creator>van Harmelen, Joanne H.</creator><creator>Shephard, Enid</creator><creator>Thomas, Robin</creator><creator>Hanke, Tomáš</creator><creator>Williamson, Anna-Lise</creator><creator>Williamson, Carolyn</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7TM</scope><scope>7QO</scope><scope>7T7</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20031001</creationdate><title>Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa</title><author>van Harmelen, Joanne H. ; Shephard, Enid ; Thomas, Robin ; Hanke, Tomáš ; Williamson, Anna-Lise ; Williamson, Carolyn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c516t-98ad923ee266f6f684e632fd334d8f2f5e85ae889a94afbe7a57580bf6c0efc93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>AIDS Vaccines - immunology</topic><topic>Amino Acid Sequence</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Chromium Radioisotopes</topic><topic>Clinical trials</topic><topic>Construction</topic><topic>Cytotoxicity Tests, Immunologic</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA vaccination</topic><topic>DNA, Complementary - immunology</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gag</topic><topic>Genes</topic><topic>Genes, gag - genetics</topic><topic>Genomes</topic><topic>HeLa Cells</topic><topic>HIV</topic><topic>HIV-1 - immunology</topic><topic>HIV-1 subtype C</topic><topic>Human immunodeficiency virus</topic><topic>Human immunodeficiency virus 1</topic><topic>Humans</topic><topic>Immunization</topic><topic>Interferon-gamma - metabolism</topic><topic>Lymphocytes</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Microbiology</topic><topic>Molecular Sequence Data</topic><topic>Peptides</topic><topic>Proteins</topic><topic>South Africa</topic><topic>T-Lymphocytes, Regulatory - immunology</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Vaccines, DNA - immunology</topic><topic>Virology</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Harmelen, Joanne H.</creatorcontrib><creatorcontrib>Shephard, Enid</creatorcontrib><creatorcontrib>Thomas, Robin</creatorcontrib><creatorcontrib>Hanke, Tomáš</creatorcontrib><creatorcontrib>Williamson, Anna-Lise</creatorcontrib><creatorcontrib>Williamson, Carolyn</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Nucleic Acids Abstracts</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Harmelen, Joanne H.</au><au>Shephard, Enid</au><au>Thomas, Robin</au><au>Hanke, Tomáš</au><au>Williamson, Anna-Lise</au><au>Williamson, Carolyn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2003-10-01</date><risdate>2003</risdate><volume>21</volume><issue>27</issue><spage>4380</spage><epage>4389</epage><pages>4380-4389</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>A candidate DNA vaccine pTHgagC expressing the immunodeficiency virus-1 (HIV-1)
gag gene from South African isolate Du422 was constructed and characterised. The isolate was selected on the basis of being the closest to the South African subtype C consensus sequence. Sequence analysis of cytotoxic T lymphocyte (CTL) epitopes showed that HIV subtype C-infected individuals have CTL responses to a number of epitopes present in the vaccine, but also revealed a more limited presence of subtype A- and any B-derived epitopes. A high level of expression of the immunogen was demonstrated in human cells and a potent, long-lived CTL response to a single inoculation of the DNA vaccine was elicited in BALB/c mice, which could be significantly increased by a boost vaccination at 4 weeks. This is the first candidate HIV-1 DNA vaccine employing the South African subtype C sequences, and constitutes a part of a vaccine scheduled to enter a clinical evaluation in South Africa in 2004.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>14505921</pmid><doi>10.1016/S0264-410X(03)00406-7</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2003-10, Vol.21 (27), p.4380-4389 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_18872695 |
| source | MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
| subjects | AIDS Vaccines - immunology Amino Acid Sequence Animals Biological and medical sciences Chromium Radioisotopes Clinical trials Construction Cytotoxicity Tests, Immunologic Deoxyribonucleic acid DNA DNA vaccination DNA, Complementary - immunology Fundamental and applied biological sciences. Psychology Gag Genes Genes, gag - genetics Genomes HeLa Cells HIV HIV-1 - immunology HIV-1 subtype C Human immunodeficiency virus Human immunodeficiency virus 1 Humans Immunization Interferon-gamma - metabolism Lymphocytes Mice Mice, Inbred BALB C Microbiology Molecular Sequence Data Peptides Proteins South Africa T-Lymphocytes, Regulatory - immunology Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Vaccines, DNA - immunology Virology Viruses |
| title | Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T13%3A57%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Construction%20and%20characterisation%20of%20a%20candidate%20HIV-1%20subtype%20C%20DNA%20vaccine%20for%20South%20Africa&rft.jtitle=Vaccine&rft.au=van%20Harmelen,%20Joanne%20H.&rft.date=2003-10-01&rft.volume=21&rft.issue=27&rft.spage=4380&rft.epage=4389&rft.pages=4380-4389&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/S0264-410X(03)00406-7&rft_dat=%3Cproquest_cross%3E3386726971%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1549344894&rft_id=info:pmid/14505921&rft_els_id=S0264410X03004067&rfr_iscdi=true |